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Abstract: A key event in Alzheimer’s disease (AD) is the production of amyloid-β (Aβ) 
peptides and the loss of synapses. In cultured neurons Aβ triggered synapse damage as 
measured by the loss of synaptic proteins. α-synuclein (αSN), aggregates of which 
accumulate in Parkinson’s disease, also caused synapse damage. Synapse damage was 
associated with activation of cytoplasmic phospholipase A2 (cPLA2), an enzyme that 
regulates synapse function and structure, and the production of prostaglandin (PG) E2. In 
synaptosomes PGE2 increased concentrations of cyclic adenosine monophosphate (cAMP) 
which suppressed the activation of cPLA2 demonstrating an inhibitory feedback system. 
Thus, Aβ/αSN-induced activated cPLA2 produces PGE2 which increases cAMP which in 
turn suppresses cPLA2 and, hence, its own production. Neurons pre-treated with 
pentoxifylline and caffeine (broad spectrum phosphodiesterase (PDE) inhibitors) or the 
PDE4 specific inhibitor rolipram significantly increased the Aβ/αSN-induced increase in 
cAMP and consequently protected neurons against synapse damage. The addition of cAMP 
analogues also inhibited cPLA2 and protected neurons against synapse damage. These results 
suggest that drugs that inhibit Aβ-induced activation of cPLA2 and cross the blood–brain 
barrier may reduce synapse damage in AD. 
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1. Introduction 
The amyloid hypothesis maintains that the key event in the pathogenesis of Alzheimer’s disease  
(AD) is the proteolytic cleavage of the amyloid precursor protein to form neurotoxic amyloid-β (Aβ) 
peptides [1]. The accumulation of Aβ leads to the disruption of neuronal processes, abnormal 
phosphorylation of tau and synapse dysfunction. The progressive dementia associated with AD is 
thought to be due to synaptic failure [2] and a reduction in synaptic proteins correlates strongly with 
cognitive decline [3,4]. 
Some of the events that lead to neurodegeneration in AD can be examined by incubating cultured 
neurons with Aβ peptides. Soluble Aβ oligomers are recognized as the primary mediators of synapse 
damage and dementia has been recognized [5,6] and in these studies soluble Aβ oligomers derived from 
the brain of an Alzheimer’s patient [7] were used. The effects of Aβ oligomers on neurons were 
examined by measuring the amounts of synaptic proteins, as a marker of synapse density [8]. The Aβ 
oligomers were active at picomolar concentrations, similar to the concentrations of Aβ found within the 
brain [9]. Synapse damage is also a feature of other neurodegenerative diseases including Parkinson’s 
disease (PD) and dementia with Lewy bodies [10]. The pathology of these diseases is associated with 
the formation of oligomeric α-synuclein (αSN) [11,12] and preparations of αSN oligomers trigger 
synapse damage in cultured neurons [13]. 
In the current study, we show that phosphodiesterase (PDE) inhibitors protect cultured neurons 
against Aβ and αSN-induced synapse damage. The protective effect of PDE inhibitors was related to its 
effects upon the concentrations of cyclic adenosine monophosphate (cAMP) within synapses. Thus, PDE 
inhibitors enhanced the Aβ/αSN-induced increase of cAMP in synapses. High concentrations of cAMP 
suppressed the Aβ/αSN-induced activation of cytoplasmic phospholipase A2 (cPLA2), a key enzyme in 
synapse function and structure [14]. In addition, we demonstrate the presence of an inhibitory feedback 
system whereby prostaglandin (PG)E2, a product of cPLA2 activation, increased concentrations of cAMP 
within synapses. The cAMP inhibited the activation of cPLA2 and hence its own production. 
2. Experimental Section 
2.1. Primary Cortical Neuronal Cultures 
Neurons were prepared from the cerebral cortices of mouse embryos (day 15.5) as described [14]. 
Neurons were plated at 2 × 105 cells/well in 48 well plates (coated with poly-L-lysine) in Ham’s F12 
containing 5% foetal calf serum for 2 h. Cultures were shaken (600 r.p.m for 5 min) and non-adherent 
cells removed by 3 washes in PBS. Neurons were then grown in neurobasal medium containing B27 
components supplemented with 5 nM brain derived nerve growth factor for 10 days. Immunohistochemistry 
showed that the cells were greater than 90% neurofilament positive. All experiments were performed in 
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accordance with European regulations (European Community Council Directive, 1986, 56/609/EEC) 
and approved by the Royal Veterinary College ethical committee. 
Neurons were pre-treated with test compounds for 1 h before the addition of peptides or a PLA2 
isolated from the venom of the Mozambique spitting cobra (Sigma, Poole, UK) for 24 h. They were then 
homogenized in an extraction buffer containing 150 mM NaCl, 10 mM Tris-HCl pH 7.4, 10 mM EDTA, 
0.5% Nonidet P-40, 0.5% sodium deoxycholate, 0.2% sodium dodecyl sulphate (SDS) and mixed 
protease inhibitors (4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride, Aprotinin, Leupeptin, 
Bestatin, Pepstatin A and E-46) (Sigma) and a phosphatase inhibitor cocktail including PP1, PP2A, 
microcystin LR, cantharidin and p-bromotetramisole (Sigma) at 106 cells/mL. Nuclei and cell debris was 
removed by centrifugation (1000× g for 5 min). 
2.2. Isolation of Synaptosomes 
Synaptosomes were prepared from 106 neurons homogenized at 4 °C in 1 mL of SED solution (0.32 M 
sucrose, 50 mM Tris-HCl pH 7.2, 1 mM EDTA, and 1 mM dithiothreitol). The supernatant was 
transferred to a 4-step gradient of 3%, 7%, 15%, and 23% Percoll in SED solution and centrifuged at 
16,000× g for 30 min at 4 °C. The synaptosomes were collected from the interface of the 15% and 23% 
Percoll steps, washed (16,000× g for 30 min at 4 °C) and suspended in neurobasal medium containing 
B27 components. Freshly prepared synaptosomes were pre-treated ±drugs and incubated with peptides 
for 1 h. Treated synaptosomes were homogenized in extraction buffer (as above). The amounts of cAMP 
within synaptosomes were determined using a kit (Enzo Life Sciences, Farmingdale, NY, USA). 
2.3. Activated cPLA2 ELISA 
The activation of cPLA2 is accompanied by phosphorylation of the 505 serine residue creating a 
unique epitope that can be recognized by specific antisera. Maxisorb immunoplates (Nunc, Roskilde, 
Denmark) were coated with 0.5 µg/mL of the mouse anti-cPLA2 monoclonal antibody (mAb) (clone 
CH-7 (Upstate)) and then blocked with 10% milk powder. Samples were added for 1 h and bound 
activated cPLA2 was detected using rabbit polyclonal anti-phospho-cPLA2 (Cell Signaling Technology, 
Danvers, MA, USA) followed by biotinylated anti-rabbit IgG (Sigma), extravidin-alkaline phosphatase 
and 1 mg/mL 4-nitrophenyl phosphate. Samples were expressed as “units activated cPLA2” where 1 
units was the amount of activated cPLA2 in control synaptosomes. 
2.4. Synaptophysin ELISA 
The amounts of synaptophysin in neurons were measured by ELISA as described [8]. Maxisorb 
immunoplates were coated with an anti-synaptophysin mouse mAb MAB368 (Millipore, Billerica, MA, 
USA) and blocked with 5% milk powder. Samples were added for 1 h and bound synaptophysin was 
detected using rabbit polyclonal anti-synaptophysin antibodies (Abcam, Cambridge, UK) followed by a 
biotinylated anti-rabbit IgG, extravidin-alkaline phosphatase and 1 mg/mL 4-nitrophenol phosphate. 
Absorbance was measured on a microplate reader at 405 nm. Samples were expressed as “units 
synaptophysin” where 100 units was defined as the amount of synaptophysin in 106 control neurons. 
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2.5. Western Blotting 
Samples were mixed with Laemmli buffer containing β-mercaptoethanol, heated to 95 °C for 5 min 
and proteins were separated by electrophoresis on 15% polyacrylamide gels (PAGE). Proteins were 
transferred onto a Hybond-P PVDF membrane by semi-dry blotting. Membranes were blocked using 
10% milk powder; synaptophysin was detected with MAB368 (Abcam), vesicle-associated membrane 
protein (VAMP)-1 with mAb 4H302 (Abcam), synapsin-1 with a rabbit polyclonal antibody (515200, 
Invitrogen, Waltham, MA, USA) and caveolin with rabbit polyclonal antibodies (Upstate, Damstadt, 
Germany). These were visualized using a combination of biotinylated anti-mouse/rat/rabbit IgG 
(Sigma), extravidin-peroxidase and enhanced chemiluminescence. 
2.6. Peptides 
Recombinant human αSN and βSN were obtained from Sigma. Stock solutions of peptides were 
thawed on the day of use and mixed in culture medium. Mixtures were subjected to vigorous shaking 
(disruptor genie, full power for 10 min) before they were added to neurons. 
2.7. Preparation of Aβ-Containing Medium 
The temporal lobe from a 78 year old female with a clinical, and pathologically-confirmed, diagnosis 
of Alzheimer’s disease, was supplied by Asterand, an international supplier of human tissue. Soluble 
extracts were prepared using methodology as described [15]. Briefly, brain tissue was cut into pieces of 
approximately 100 mg and added to 2 mL tubes containing lysing matrix D beads (Q-Bio, Cambridge, 
UK). Neurobasal medium containing B27 components was added so that there was the equivalent of 100 
mg brain tissue/mL. The tubes were shaken for 10 min (Disruptor genie, Scientific Instruments, Oxford, 
UK) for 3 times and tubes centrifuged at 16,000× g for 10 min to remove cell debris. Soluble material 
was prepared by passage through a 50 kDa filter (Sartorius, Damstadt, Germany). The amounts of Aβ in 
each soluble extract were measured by ELISA (see below) and the supernatant stored at −80 °C. 
2.8. Immunodepletions 
Brain extracts were incubated with mAb 4G8 (reactive with amino acids 17–24 of Aβ) and incubated 
at 4 °C on rollers for 1 h. Protein G microbeads (Sigma) were added (10 µL/mL) for 30 min and protein 
G-antibody complexes were removed by centrifugation (16,000× g for 10 min). Mock-depletions 
involved incubating brain extracts with an isotype control followed by protein G microbeads under the 
same conditions as above. Depleted media was filtered before further use. 
2.9. Aβ42 ELISA 
Maxisorb immunoplates were coated with mAb 4G8 (epitope 17–24) (Covance, Princeton, NJ, USA). 
Plates were blocked with 5% milk powder in PBS-tween and samples were applied. The detection 
antibody was an Aβ42 selective rabbit mAb BA3-9 (Covance) followed by biotinylated anti-rabbit IgG 
(Sigma), extravidin-alkaline phosphatase and 1 mg/mL 4-nitrophenol phosphate. Absorbance was read 
in a spectrophotometer at 405 nm. Results were calculated by comparison to synthetic Aβ42 (Bachem, 
Bubendorf, Switzerland). 
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2.10. Aβ40 ELISA 
Maxisorb immunoplates were coated with mAb 4G8 (epitope 17–24) (Covance, Maidenhead, UK). 
Plates were blocked with 5% milk powder and samples were applied. The detection antibody was  
an Aβ40 selective rabbit polyclonal PC-149 (Merck, Damstadt, Germany) followed by biotinylated  
anti-rabbit IgG, extravidin alkaline phosphatase and 1 mg/mL 4-nitrophenol phosphate, Absorbance was 
read in a spectrophotometer at 405 nm. Results were calculated by comparison to serial dilutions of 
synthetic Aβ40 (Bachem, Bubendorf, Switzerland). 
2.11. Drugs 
Arachidonyl trifluoromethyl ketone (AACOCF3), aspirin, caffeine, pentoxifylline, AH13205, 
BWA868C, dibutyryl cAMP, 8-bromo-cAMP, ibuprofen, methyl arachidonyl fluorophosphonate 
(MAFP) and prostaglandins D2, E2, I2 and J2 were obtained from Sigma. Stock solutions were dissolved 
in ethanol or di-methyl sulphoxide and diluted in neurobasal medium to obtain final working 
concentrations. Control medium consisted of equivalent dilutions of ethanol or di-methyl sulphoxide in 
neurobasal medium. 
2.12. Statistical Methods 
Differences between treatment groups were assessed using Student’s, paired t-tests. 
3. Results and Discussion 
3.1. Aβ Triggered Synapse Damage 
Immunoblots of neuronal extracts showed that the addition of brain extract causes the loss of 
synapsin-1 and vesicle-associated membrane protein (VAMP)-1 (Figure 1A). They did not affect the 
amounts of caveolin from these neurons suggesting that synapse degeneration occurred in the absence 
of any significant neuronal death. Incubation with a brain extract containing 1 nM Aβ42 caused a 
significant reduction in the synaptophysin content of neurons (Figure 1B). Brain extract depleted of Aβ 
had reduced concentrations of both Aβ40 (4.9 nM ± 0.3 to 0.3 nM ± 0.3 nM) and Aβ42 (1.2 nM ± 0.16 to 
0.11 nM ± 0.1 nM) and did not cause a significant loss of synaptophysin from neurons. These 
observations show that Aβ is a major toxin in brain extract preparations. 
3.2. Pentoxifylline Protects Neurons against Aβ-Induced Synapse Damage 
The effects of pentoxifylline, a broad spectrum PDE inhibitor, on Aβ-induced synapse damage in 
cultured neurons was studied. Firstly, the addition of 100 µM pentoxifylline alone did not affect synapses 
in cultured neurons (101 units synaptophysin ± 5 compared to 100 units synaptophysin ± 5, n = 9,  
p = 0.5). Pre-treatment with 100 µM pentoxifylline protected neurons against the Aβ-induced loss of 
synaptophysin (Figure 2A). The loss of synapses is a pathological feature that is also seen in cases of 
PD that show dementia [10] in which small oligomers of αSN accumulate at synapses [11]. The addition 
of αSN triggered the loss of synaptophysin from neurons in a tissue culture model of the synapse damage 
that occurs in Parkinson’s disease and dementia with Lewy bodies [13]. Pre-treatment with 100 μM 
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pentoxifylline protected neurons against the αSN-induced loss of synaptophysin (Figure 2B). However, 
the loss of synaptophysin from neurons incubated with a PLA2 isolated from the venom of the 
Mozambique spitting cobra) was not significantly altered by pre-treatment with pentoxifylline (Figure 2C). 
 
Figure 1. Aβ causes synapse damage in cultured neurons: (A) Immunoblots showing the 
amounts of synapsin-1, VAMP-1 and caveolin in neurons incubated with brain extract as 
shown; (B) The amounts of synaptophysin in neurons incubated with control medium (□), 
brain extract (■), Aβ-depleted brain extract (striped bar) or mock-depleted brain extract 
(hatched bar). Values are means ± SD from triplicate experiments performed 2 times (n = 6). 
* = synaptophysin significantly less than in control neurons. 
 
Figure 2. Pentoxifylline protects neurons against Aβ and αSN-induced synapse damage: The 
amounts of synaptophysin in neurons pre-treated with control medium (○) or 100 µM 
pentoxifylline (●) and incubated with Aβ42 (A), αSN (B) or snake venom PLA2 (C) as shown. 
Values are means ± SD from triplicate experiments performed 3 times (n = 9). 
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3.3. Caffeine and Rolipram Protect Neurons against Aβ and αSN-Induced Synapse Damage 
Other PDE inhibitors were tested, pre-treatment with 100 μM caffeine protected neurons against the 
Aβ-induced loss of synaptophysin (Figure 3A); the effects of caffeine were dose-dependent (Figure 3B). 
Rolipram, which selectively inhibits PDE4 [16], also protected neurons against the Aβ-induced loss of 
synaptophysin (Figure 3C). The effects of rolipram were also dose-dependent (Figure 3D). 
 
Figure 3. Caffeine and Rolipram protect neurons against Aβ-induced synapse damage: 
(A) The amounts of synaptophysin in neurons pre-treated with control medium (○) or 100 
µM caffeine (●) and incubated with Aβ42 as shown. Values are means ± SD from triplicate 
experiments performed 4 times (n = 12); (B) The amounts of synaptophysin in neurons  
pre-treated with control medium (□) or caffeine as shown (■) and incubated with 2 nM Aβ42. 
Values are means ± SD from triplicate experiments performed 3 times (n = 9); (C) The 
amounts of synaptophysin in neurons pre-treated with control medium (○) or 10 μM rolipram 
(●) and incubated with Aβ42 as shown. Values are means ± SD from triplicate experiments 
performed 4 times (n = 12); (D) The amounts of synaptophysin in neurons pre-treated with 
control medium (□) or rolipram as shown (■) and incubated with 2 nM Aβ42. Values are 
means ± SD from triplicate experiments performed 3 times (n = 9). 
3.4. PDE Inhibitors Do Not Alter the Accumulation of Aβ42 in Synapses 
The possibility that PDE inhibitors prevented synapse damage by reducing the accumulation of Aβ42 
within synapses was explored. Neurons treated with PDE inhibitors, incubated with 10 nM Aβ42 for 1 h 
and synaptosomes were isolated from these neurons. There was no significant difference in the 
concentrations of Aβ42 found in synaptosomes isolated from neurons treated with control medium and 
100 μM pentoxifylline (2.74 nM Aβ42 ± 0.5 compared with 2.87 ± 0.29, n = 9, p = 0.53) or 10 μM 
rolipram (2.74 nM Aβ42 ± 0.5 compared with 2.63 ± 0.45, n = 9, p = 0.45). 
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3.5. Aβ and αSN Increase the Concentrations of cAMP in Synaptosomes 
These results implied that the protective effect of PDE inhibitors were mediated via its inhibition of 
the PDEs and increased cAMP concentrations. To test this hypothesis we first examined the effects of 
Aβ and αSN on cAMP concentrations in synaptosomes. The addition of brain extract (Figure 4A) or 
αSN (Figure 4B) increased the concentrations of cAMP within synaptosomes in a dose-dependent 
manner, whereas the addition of control preparations (Aβ-depleted brain extract or βSN) had no 
significant effect. Next, the effect of pentoxifylline and rolipram on the concentration of cAMP in 
synaptosomes was measured. cAMP concentrations in control synaptosomes were not significantly 
affected by 100 µM pentoxifylline (0.97 units cAMP ± 0.12 compared with 1 ± 0.92, n = 9, p = 0.68) or 
10 μM rolipram (1.05 units cAMP ± 0.16 compared with 1 ± 0.92, n = 9, p = 0.51). Pre-treatment with 
either 100 µM pentoxifylline or 10 μM rolipram increased cAMP concentrations in synaptosomes 
incubated with Aβ (Figure 4C) or αSN (Figure 4D). 
 
Figure 4. PDE inhibitors enhance the Aβ and αSN-induced increase in synaptic cAMP 
concentrations in synaptosomes: (A) The amounts of cAMP in synaptosomes incubated with 
brain extract (○), Aβ-depleted brain extract (□) or mock-depleted brain extract (●). Values 
are means ± SD, from triplicate experiments performed 3 times (n = 9); (B) The amounts of 
cAMP in synaptosomes incubated with αSN (○) or βSN (●). Values are means ± SD, from 
triplicate experiments performed 3 times (n = 9). The amounts of cAMP in synaptosomes 
pre-treated with control medium (○), 100 μM pentoxifylline (●) or 10 μM rolipram (□) and 
incubated with Aβ42 (C) or αSN (D) as shown. Values are means ± SD, from triplicate 
experiments performed 3 times (n = 9). 
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3.6. cAMP Analogues Protect Neurons against Aβ and αSN-Induced Synapse Damage 
To complement the PDE inhibitor studies; the effects of two cAMP analogues (dibutyryl cAMP and 
8-bromo-cAMP) on neurons were studied. The amounts of synaptophysin in neuronal cultures was not 
significantly affected by incubation with either 100 μM dibutyryl cAMP (98 units synaptophysin ±  
7 compared with 100 units ± 6, n = 9, p = 0.4) or 100 μM 8-bromo-cAMP (97 units synaptophysin ±  
8 compared with 100 units ± 6, n = 9, p = 0.35) indicating that these drugs alone did not damage synapses. 
Pre-treatment with 100 μM dibutyryl cAMP or 100 μM 8-bromo-cAMP protected neurons against the 
loss of synaptophysin induced by either Aβ (Figure 5A) or αSN (Figure 5B), but had no effect against 
snake-venom PLA2-induced synapse degeneration (Figure 5C). 
 
Figure 5. cAMP protects neurons against Aβ and αSN-induced synapse damage: The 
amounts of synaptophysin in neurons pre-treated with control medium (○), 100 µM dibutyryl 
cAMP (□) or 100 µM 8-bromo-cAMP (■) and incubated with Aβ42 (A); αSN (B) or snake 
venom PLA2 (C) as shown. Values are means ± SD from triplicate experiments performed 
3 times (n = 9). 
3.7. PDE Inhibitors Reduce the Aβ and αSN-Induced Activation of cPLA2 in Synapses 
There is increasing evidence to implicate Aβ-induced activation of specific cell signaling pathways 
in synapse damage. For example, Aβ42 activates cPLA2 [17,18] and inhibition of cPLA2 protects cultured 
neurons against Aβ-induced synapse damage [14] and ameliorated cognitive decline in a mouse model 
of AD [19]. For these reasons the effects of PDE inhibitors and cAMP analogues on cPLA2 in 
synaptosomes were examined. The amounts of activated cPLA2 in synaptosomes was not significantly 
altered by treatment with 100 µM pentoxifylline (1.06 units cAMP ± 0.15 compared with 1 ± 0.14, n = 9, 
p = 0.52) or 10 μM rolipram (1.07 units cAMP ± 0.12 compared with 1 ± 0.92, n = 9, p = 0.44).  
The addition of Aβ or αSN increased the amounts of activated cPLA2 within synaptosomes [14].  
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Pre-treatment of synaptosomes with 100 μM pentoxifylline or 10 μM rolipram significantly reduced the 
activation of cPLA2 by Aβ (Figure 6A) and αSN (Figure 6B). Similarly, pre-treatment with 100 μM 
dibutyryl cAMP or 8-bromo-cAMP reduced the activation of cPLA2 by Aβ (Figure 6C) and by αSN 
(Figure 6D). 
 
Figure 6. cAMP reduces Aβ and αSN-induced activation of cPLA2: The amounts of 
activated cPLA2 in synaptosomes pre-treated with control medium (○), 100 μM pentoxifylline 
(●) or 10 μM rolipram (□) and incubated with Aβ42 (A) or αSN (B) as shown. Values are 
means ± SD from triplicate experiments performed 3 times (n = 9); (C) The amounts of 
activated cPLA2 in synaptosomes pre-treated with control medium (○), 100 µM dibutyryl 
cAMP (□) or 100 µM 8-bromo-cAMP (●) and incubated with Aβ42 as shown. Values are 
means ± SD from triplicate experiments performed 3 times (n = 9); (D) The amounts of 
activated cPLA2 in synaptosomes pre-treated with control medium (□), 100 µM dibutyryl 
cAMP (■) or 100 µM 8-bromo-cAMP (striped bars) and incubated with 200 nM αSN. Values 
are means ± SD from triplicate experiments performed 3 times (n = 9). 
3.8. PGE2-Mediates Aβ-Induced Increase in Camp 
Since cAMP inhibited the activation of cPLA2 and reduced synapse degeneration, the molecular 
mechanisms leading to cAMP generation within synaptosomes were examined in detail. The Aβ-induced 
increase in cAMP was significantly reduced by pre-treatment with cPLA2 inhibitors (1 μM AACOCF3 
or 1 μM MAFP) (Figure 7A) and by the cyclo-oxygenase inhibitors aspirin and ibuprofen (Figure 7B) 
suggesting that a PG is involved in the Aβ-induced increase in cAMP. The addition of 1 nM PGE2, but 
not other PGs, significantly increased cAMP concentrations in synaptosomes (Figure 7C). Since PGs 
exert their effects through specific receptors, synaptosomes were pre-treated with selective antagonists 
of prostanoid receptors. Pre-treatment of synaptosomes with the prostanoid E receptor antagonist 
AH13205 significantly reduced Aβ and αSN-induced increase in cAMP (Figure 7D). Pre-treatment of 
synaptosomes with the prostanoid D receptor antagonist BWA868C did not affect the Aβ or αSN-induced 
increase in cAMP concentrations. 
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Figure 7. The Aβ-induced increase in synaptic cAMP is caused by PGE2: (A) The amounts 
of cAMP in synaptosomes pre-treated with control medium, 1 μM AACOCF3 or 1 μM 
MAFP and incubated with control medium (□) or 1 nM Aβ42 (■). Values are means ± SD, 
from triplicate experiments performed twice (n = 6). * = cAMP significantly lower than 
synaptosomes incubated with Aβ; (B) The amounts of cAMP in synaptosomes pre-treated 
with control medium, 1 μM aspirin or 1 μM Ibuprofen and incubated with control medium 
(□) or 1 nM Aβ42 (■). Values are means ± SD, from triplicate experiments performed twice 
(n = 6). * = cAMP lower than synaptosomes incubated with Aβ; (C) The amounts of cAMP 
in synaptosomes incubated with control medium (□) or 1 nM prostaglandins as shown (■). 
Values are means ± SD, from triplicate experiments performed twice (n = 6). * = cAMP 
significantly higher than control synaptosomes; (D) The amounts of cAMP in synaptosomes 
pre-treated with control medium, 100 nM AH13205 (a prostanoid E receptor antagonist) or 
100 nM BWA868C (a prostanoid D receptor antagonist) and incubated with 1 nM Aβ42  
(■) or 100 nM αSN (□). Values are means ± SD, from triplicate experiments performed twice 
(n = 6). 
3.9. PGE2 Inhibits the Activation of cPLA2 in Synapses 
PGE2 is involved in synapse function and regulates synaptic plasticity [20]. The observation that 
PGE2 increased the concentrations of cAMP in synaptosomes and that cAMP suppresses Aβ and  
αSN-induced synapse damage suggests the presence of an inhibitory feedback system within synapses. 
We hypothesised that the Aβ/αSN-induced activation of cPLA2 results in the production of PGE2 which 
increases cAMP and inhibits cPLA2 activation (Figure 9). This hypothesis was tested by treating 
synaptosomes with either 1 nM PGE2 or 1 nM PGD2 prior to incubation with Aβ or αSN. Pre-treatment 
of synaptosomes with PGE2, but not PGD2, significantly reduced both Aβ (Figure 8A) and αSN  
(Figure 8B)-induced activation of cPLA2. 
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Figure 8. PGE2 reduces Aβ and αSN-induced activation of synaptic cPLA2: The amounts of 
activated cPLA2 in synaptosomes pre-treated for with control medium (○), 1 nM PGE2 (●) 
or 1 nM PGD2 (■) and incubated with Aβ42 (A) or αSN (B) as shown. Values are means ± SD 
from triplicate experiments performed 3 times (n = 9). 
 
Figure 9. Feedback inhibition of cPLA2 by cAMP: Cartoon showing the proposed inhibitory 
feedback system that regulates the activation of cPLA2 in synapses. The presence of Aβ 
activates cPLA2 leading to the production of PGE2 high concentrations of which cause 
synapse damage. However, PGE2 also increases concentrations of cAMP which in turn 
inhibits the activation of cPLA2 completing an inhibitory feedback system. In control 
synapses cAMP is degraded by PDEs. Inhibition of PDEs by either pentoxifylline or rolipram 
results in higher concentrations of cAMP within synapses. Higher cAMP concentrations have 
a stronger inhibitory feedback signal and reduce the Aβ-induced activation of cPLA2. 
4. Discussion 
Neurons were incubated with disease-related peptides to model the synapse damage that is a 
prominent feature of AD and Parkinson’s disease. The addition of Aβ and αSN to neurons triggered 
synapse damage at concentrations that did not affect neuronal survival [13], correlating with observations 
that synapse damage and clinical symptoms (due to the loss of neuron to neuron communication) can 
develop in these diseases before any gross neuronal loss is observed [2]. Such observations are consistent 
with the hypothesis that Aβ and αSN are responsible for the cognitive defects that occur during AD and 
Parkinson’s disease [2,10]. 
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Drugs that maintain synapse function in the presence of Aβ and αSN may provide therapeutic benefit 
for patients when used as an adjunct to conventional Aβ lowering treatments. Here we show that some 
PDE inhibitors including pentoxifylline and caffeine protected neurons against Aβ and αSN-induced 
synapse damage. As some epidemiological studies concluded that regular consumption of coffee is 
associated with protection against AD, Parkinson’s disease and other dementias [21,22] and caffeine 
(1,3,7-trimethylxanthine) is the major active compound within coffee, it has been identified as a possible 
mediator of coffee’s neuroprotective effects. However, although caffeine protected neurons against Aβ 
and αSN-induced synapse damage, the concentrations required were higher than those normally found 
within the blood. The PDEs encompass a large family of proteins, each with specific cellular locations 
and substrate specificities. Currently, PDE4 is the subject of scrutiny for its role in neurodegenerative 
diseases as the selective PDE4 inhibitor rolipram improved cognitive functions in AD models [23–25]. 
Here we show that rolipram also protected neurons against Aβ and αSN-induced synapse damage. 
Sildenafil, a PDE5 inhibitor, also improved synaptic function in a mouse model of AD [26] suggesting 
the involvement of multiple PDEs in synapse function. Pentoxifylline did not protect neurons against a 
PLA2 derived from snake venom, which has a direct effect upon the pre-synaptic membrane [27] 
indicating that pentoxifylline acts of specific pathways. 
Possible mechanisms of PDE inhibitor-mediated protection were examined. Aβ accumulates within 
synapses [28,29] and the high potency of Aβ oligomers suggests that their effects are mediated by 
specific receptors. However, the PDE inhibitors did not alter the concentrations of Aβ42 within synapses 
indicating that Aβ42 does not have a direct effect on synapses, rather that its actions are dependent upon 
specific pathways. 
Our observations that Aβ and αSN increased the concentrations of cAMP in synaptosomes and reports 
that pre-synaptic cAMP and cAMP-dependent protein kinases affected neurotransmission [30,31] 
suggest that cAMP has a regulatory role at the synapse. As the PDEs degrade cAMP it was not surprising 
to observe that pentoxifylline and rolipram accentuated the Aβ and αSN-induced increase in cAMP in 
synaptosomes. Collectively these observations suggest that high concentrations of cAMP protect 
synapses, a hypothesis strengthened by our observation that cAMP analogues protected neurons against 
Aβ and αSN-induced synapse damage. The next step was to determine how cAMP might protect 
synapses. Both PDE inhibitors and cAMP analogues reduced the Aβ and αSN-induced activation of 
cPLA2 a key enzyme in synapse damage [14,19,32], in synaptosomes; an observation that is consistent 
with reports that cAMP inhibits PLA2 in other cell types [33]. 
We sought to determine the molecular mechanism underlying the Aβ and αSN-induced increase in 
cAMP. Selective cPLA2 inhibitors reduced the Aβ-induced increase in cAMP suggesting an inhibitory 
feedback effect whereby cAMP inhibits enzymes responsible for its own production. The activation of 
cPLA2 leads to the formation of prostaglandins and leucotrienes [34]. The Aβ-induced increase in cAMP 
was also reduced by pre-treating synaptosomes with the cyclo-oxygenase inhibitors aspirin and 
ibuprofen which prevent the production of prostaglandins. More specifically, PGE2, but not other PGs, 
increased synaptic cAMP concentrations and both Aβ and αSN-induced increases in synaptic cAMP 
were reduced by pre-treatment with a selective prostanoid E receptor antagonist indicating that PGE2 is 
the key prostaglandin regulating Aβ and αSN-induced synaptic cAMP production. 
PGE2 has a complicated role at the synapse; although it regulates synaptic plasticity [35], higher 
concentrations trigger synapse damage [14]. We hypothesize that PGE2 acts as a feedback inhibitor of 
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cPLA2 as illustrated in Figure 9. Thus, activation of cPLA2 leads to the production of PGE2 which 
increases the cAMP concentrations that have an inhibitory effect upon cPLA2 and hence its own 
production. This hypothesis was supported by our observations that PGE2 increased cAMP and 
significantly reduced the Aβ and αSN-induced activation of cPLA2. We propose that the inhibition of 
PDEs enhances the PGE2-induced rise in cAMP at the synapse, thus increasing the inhibition of cPLA2 
and protecting the synapse. 
5. Conclusions 
In summary, we showed that some PDE inhibitors protect neurons against the synapse damage 
induced by Aβ or αSN. Their protective effect was associated with increased concentrations of cAMP 
in synapses and suppression of cPLA2, effects that were mimicked by cAMP analogues. We also 
demonstrate the presence of an inhibitory feedback system in which cAMP suppresses the activation of 
cPLA2 and the production of PGE2 and hence its own production. 
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